MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.06 EUR | 0.00% |
|
+3.90% | +29.80% |
| Sales 2024 * | 4M 4.28M | Sales 2025 * | 4.4M 4.7M | Capitalization | 105M 112M |
|---|---|---|---|---|---|
| Net income 2024 * | -29M -31.01M | Net income 2025 * | -29M -31.01M | EV / Sales 2024 * | 31.9 x |
| Net Debt 2024 * | 22.5M 24.06M | Net Debt 2025 * | 53.7M 57.42M | EV / Sales 2025 * | 36.1 x |
| P/E ratio 2024 * |
-3.55
x | P/E ratio 2025 * |
-3.52
x | Employees | 56 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on MaaT Pharma
More press releases
More news
| 1 week | +3.90% | ||
| Current month | +2.95% | ||
| 1 month | -2.58% | ||
| 3 months | +26.54% | ||
| 6 months | +29.06% | ||
| Current year | +29.80% |
1 week
8.60
9.06
1 month
8.609.90
Current year
6.409.90
1 year
4.509.90
3 years
4.5014.40
5 years
4.5014.40
10 years
4.5014.40
| Managers | Title | Age | Since |
|---|---|---|---|
Hervé Affagard
FOU | Founder | - | 13-12-31 |
Siân Crouzet
DFI | Director of Finance/CFO | - | 15-12-31 |
| Chief Tech/Sci/R&D Officer | - | 22-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 13-12-31 | |
Claude Bertrand
BRD | Director/Board Member | 61 | 20-07-15 |
Muriel Prudent
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 9.06 | 0.00% | 174 |
| 24-04-25 | 9.06 | +2.95% | 684 |
| 24-04-24 | 8.8 | +0.69% | 218 |
| 24-04-23 | 8.74 | -0.91% | 358 |
| 24-04-22 | 8.82 | +1.15% | 1,965 |
Real-time Euronext Paris, April 26, 2024 at 08:05 am EDT
More quotes
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
2024-05-13
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.06
EUR
Average target price
15.5
EUR
Spread / Average Target
+71.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.80% | 112M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MAAT Stock
